One of Biogen’s top execs is jumping ship for a new job as the bellwether Boston biotech undergoes some lengthy soul searching in the wake of a Phase III catastrophe.
In order to read this article, you must be an Endpoints News subscriber. (It's free to subscribe.)
The best place to read Endpoints News? In your inbox.
Comprehensive daily news report for those who discover, develop, and market drugs. Join 51,200+ biopharma pros who read Endpoints News by email every day.Free Subscription